Mettler-Toledo (MTO) AI Stock Analysis
Mettler-Toledo
(XETRA:MTO)
No summary available
Mettler-Toledo (MTO) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 33.63B
- Dividend Yield
- ―
- Average Volume (3M)
- 3
- Price to Earnings (P/E)
- 37.7
- Beta (1Y)
- 0.72
- Revenue Growth
- -0.31%
- EPS Growth
- 4.88%
- Country
- Germany
- Employees
- 16,600
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Mettler-Toledo Business Overview & Revenue Model
Company Description
Mettler-Toledo International Inc. (MTD) is a global enterprise dedicated to the production and provision of precision instruments and related services. The company's operations are strategically organized across five geographical divisions: its domes...
Mettler-Toledo Earnings Call Summary
The call conveyed a decidedly positive operational and financial picture: revenue growth beat expectations, margins expanded, adjusted EPS rose ~14% and full-year guidance was raised. Strength was broad-based (China, emerging markets, Lab, Industrial automation, services) and driven by pricing, productivity initiatives (Spinnaker) and product innovation. Notable risks and noise included one-time tariff refund accounting that reduced reported sales, timing-related weakness in Product Inspection and certain projects, EU chemical exposure to energy costs, higher transportation costs, and short backlog that increases near-term sensitivity. On balance, management presented confidence in execution and raised guidance, indicating momentum into the second half despite identifiable near-term risks.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
The company raised its full‑year 2026 guidance, now calling for local‑currency sales growth of approximately 4%–5% (organic 3%–4%) excluding the one‑time tariff refunds, with adjusted EPS guidance of $47.15–$47.50 (up ~10%–11%, or ~11%–12% excluding currency); at recent spot rates FX is estimated to be a ~1% benefit to sales and a slight headwind to EPS. For Q3 2026 the company expects local‑currency sales growth of ~4% (including ~0.5% from acquisitions) and adjusted EPS of $12.00–$12.15 (up ~8%–9%, or ~9%–10% excluding currency); currency is expected to be neutral to Q3 sales and a ~1% headwind to Q3 EPS. Additional 2026 assumptions: total amortization ~$78M (purchased intangibles ~$28M pretax, ≈$1.07), interest expense ~$67M, other income ~$24M, effective tax rate ~19%, free cash flow ~ $900M (≈6% growth per share), and share repurchases increased to $875M for the year (vs. $825M annualized in H1).
Mettler-Toledo Risk Analysis
Mettler-Toledo disclosed 29 risk factors in its most recent earnings report. Mettler-Toledo reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksMettler-Toledo Peers Comparison
Overall Rating
TMO76.9Outperform
ILMN76Outperform
WAT76Outperform
DHR73Outperform
A70Outperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 77Outperform | $257.71B | 35.95 | 13.31% | 0.27% | 8.27% | 9.59% | |
| 76Outperform | $35.63B | 38.47 | 31.45% | ― | 6.00% | 31.48% | |
| 76Outperform | $45.46B | 111.77 | 1.88% | ― | 52.47% | -63.86% | |
| 73Outperform | $163.38B | 37.26 | 8.18% | 0.67% | 5.52% | 25.53% | |
| 70Outperform | $49.30B | 33.79 | 20.47% | 0.59% | 8.60% | 19.07% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:MTO | Mettler-toledo International | 1499.00 | 297.00 | 24.71% | |
| A | Agilent Technologies | 171.99 | 27.00 | 18.62% | |
| DHR | Danaher Corporation | 227.97 | 15.71 | 7.40% | |
| ILMN | Illumina | 226.58 | 109.72 | 93.89% | |
| TMO | Thermo Fisher Scientific | 682.65 | 119.39 | 21.20% | |
| WAT | Waters Corp | 449.53 | 82.19 | 22.37% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.